Lipid Metabolism and Lipoprotein Production in Kidney

在正常情况下，肾脏中没有观察到脂质堆积。然而，在进行性肾脏疾病中，脂质通常积聚在肾脏的肾小管上皮细胞中。我们之前已经证明，LXR激动剂，一种已知能激活肝脏脂肪代谢的药物，可以减少疾病肾脏中积累的脂肪，并在动物模型中减少尿蛋白水平。在本研究中，我们提出该药对肾脏载脂蛋白M的诱导作用是其对肾脏疾病治疗作用的一部分。

In normal condition, lipid accumulation is not observed in the kidney. In progressive kidney diseases, however, lipid is commonly accumulated in tubular epithelial cells of the kidney. We previously showed that LXR agonist, a drug known to activate lipid metabolism in the liver, reduced accumulated lipid in diseased kidney, and also urinary protein level in an animal model. In the present study, we have proposed that the induction of apolipoprotein M in the kidney by the drug is a part of its therapeutic effect for the kidney disease.